[Clinical studies with a new antigonadotropin: Danazol] Experimentation clinique d'un nouvel antigonadotrope: le Danazol.
Danazol (2-3-isoxazol-17alpha-ethinyl-testosterone) was prescribed to 42 normally cycling women, some endometriosis patients, some primary and secondary infertility patients, 6 girls with precocious puberty, several women with breast disorders, 48 women for contraception, and some normal men. At 800 mg/day for 21-240 days, Danazol inhibited follicle-stimulating hormone (FSH) and luteinizing hormone (LH) peaks and temperature curves and caused amenorrhea in 31 normal women. All began menstruating 4-6 weeks after stopping. Lesions regressed in 55% of the endometriosis patients, 37% felt subjective improvement; 2 who were sterile for 9 years conceived on a schedule of 800 mg/day,, reduced to 600 or 400 mg after amenorrhea was established. 42% of the combined endometriosis and infertile women conceived within 4 months after taking 200 mg/day for 3 months. In 6 girls with precocious puberty, 200 mg/day reversed menstruation and breast and pubic hair development and permitted growth and normal bone age. Danazol is being prescribed for breast disorders such aspremenstrual mastodyny, adolescent hypertrophy, and dystrophy. Doses of 200 mg/day prevented ovulation; 100 mg/day permitted normal menstruation in most subjects but altered cervical mucous. 48 women taking Danazol failed to become pregnant. In men, 200 mg/day lowered plasma testosterone; 600 mg inhibited gonadotropins and markedly decreased testosterone; 800 mg left spermatogenesis unaffected.